The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy
Open accessAbstract
This article seeks to provide the practising clinician with guidance on the pharmacological management of tic disorders in children and adults. We performed a systematic review of the literature on the treatment of tic disorders. A multi-institutional group of 14 experts in psychiatry, child psychiatry, neurology, pediatrics, and psychology engaged in a consensus meeting. The evidence was presented and discussed, and nominal group techniques were employed to arrive at consensus on recommendations. A strong recommendation is made when the benefits of treatment clearly outweigh the risks and burdens, and can apply to most patients in most circumstances without reservation. With a weak recommendation, the benefits, risks, and burdens are more closely balanced, and the best action may differ depending on the circumstances. Based on these principles, weak recommendations were made for the use of pimozide, haloperidol, fluphenazine, metoclopramide (children only), risperidone, aripiprazole, olanzapine, quetiapine, ziprasidone, topiramate, baclofen (children only), botulinum toxin injections, tetrabenazine, and cannabinoids (adults only). Strong recommendations were made for the use of clonidine and guanfacine (children only). While the evidence supports the efficacy of many of the antipsychotics for the treatment of tics, the high rates of side effects associated with these medications resulted in only weak recommendations for these drugs. In situations where tics are not severe or disabling, the use of a medication with only a weak recommendation is not warranted. However, when tics are more distressing and interfering, the need for tic suppression to improve quality of life is stronger, and patients and clinicians may be more willing to accept the risks of pharmacotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Treatment of ADHD in children with tics: A randomized controlled trial
The Tourette’s Syndrome Study Group (2002) · Neurology · doi:10.1212/wnl.58.4.527 · Cited by 504
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-25028 · Cited by 256
CHAPPELL, P. B., RIDDLE, M. A., SCAHILL, L., LYNCH, K. A., SCHULTZ, R., ARNSTEN, A., LECKMAN, J. F., & COHEN, D. J. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199509000-00010 · Cited by 250
Transdermal Nicotine and Haloperidol in Tourette's Disorder: A Double-Blind Placebo-Controlled Study
Silver, A. A., Shytle, D., Philipp, M. K., Wilkinson, B. J., McConville, B., & Sanberg, P. R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0908 · Cited by 111
Toren, P., Weizman, A., Ratner, S., Cohen, D., & Laor, N. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0413 · Cited by 60
Cited by
Gilles de la Tourette syndrome
Robertson, M. M., Eapen, V., Singer, H. S., Martino, D., Scharf, J. M., Paschou, P., Roessner, V., Woods, D. W., Hariz, M., Mathews, C. A., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.97 · Cited by 347
Ganos, C., & Martino, D. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.008 · Cited by 119
Focus on Guanfacine Extended-release: A Review of its Use in Child and Adolescent Psychiatry.
(2014) · Europe PMC (PubMed Central) · Cited by 12
Changes in mindfulness following repetitive transcranial magnetic stimulation for mood disorders.
Leong, K., Chan, P., Grabovac, A., Wilkins-Ho, M., & Perri, M. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305801206 · Cited by 11
Metadata
- Authors
- Pringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Luscombe, S., Steeves, T., & Sandor, P.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2012-03
- Volume
- 57
- Issue
- 3
- Pages
- 133-143
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2156521414
- Cited by
- 191
- References
- 9
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy. https://app.cochat.ai/papers/10.1177/070674371205700302
- The paper
- Pringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Luscombe, S., Steeves, T., & Sandor, P. (2012). Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371205700302
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.